Bicycle Therapeutics Plc Liquidation Value

BCYC Pharmaceuticals

Cash & Equivalents

$559.47M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $559.47M
Total Obligations: -$77.89M
$481.58M
Per share: $6.91
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $559.47M
AR: $0
Total Obligations: -$77.89M
$481.58M
Per share: $6.91
Period: 2026-03-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $559.47M
AR: $0
Inventory: N/A
Total Obligations: -$77.89M
$481.58M
Per share: $6.91
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Inventory: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$481.58M$6.91
Liquid Liquidation Value$481.58M$6.91
Operating Liquidation Value$481.58M$6.91

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-04-30. View on SEC EDGAR →

Cash & Equivalents$559.47M
Accounts Receivable$0
InventoryN/A
Current Liabilities$48.89M
Long-term Debt (?)N/A
Op. Lease Liability (?)$13.87M
Finance Lease (?)$605,000
Shares Outstanding69.7M

Explore all 112 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$559.47M$0N/A$5.97M$48.89MN/A$13.87M$605,000
2025-12-31$628.11M$0N/A$9.67M$56.98MN/A$14.10M$669,000
2025-09-30$648.33M$0N/A$12.65M$69.28MN/A$981,000$740,000
2025-06-30$721.45M$0N/A$18.26M$77.42MN/A$1.76M$789,000
2025-03-31$792.97M$136,000N/A$11.11M$57.62MN/A$2.61M$793,000
2024-12-31$879.52M$0N/A$15.79M$67.23MN/A$3.99M$817,000
2024-09-30$890.86M$0N/A$5.71M$56.41MN/A$5.53M$920,000
2024-07-09N/AN/AN/AN/AN/A$30.00MN/AN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-04-30 View
2025-12-31 10-K 2026-03-17 View
2025-09-30 10-Q 2025-10-30 View
2025-06-30 10-Q 2025-08-08 View
2025-03-31 10-Q 2025-05-01 View
2024-12-31 10-K 2025-02-25 View
2024-09-30 10-Q 2024-10-31 View
2024-06-30 10-Q 2024-08-06 View

AI Insights

AI Insight·Generated 2026-05-06

Bicycle Therapeutics plc (BCYC) presents a materially negative equity recovery posture under liquidation analysis as of March 31, 2026, despite a positive book stockholders' equity of $554.3M. The dominant asset is cash and cash equivalents of $559.5M, which recovers at par under the liquidation lens. Total assets of $652.4M include $619.1M current assets (principally cash), $5.7M net PP&E, $14.5M operating lease ROU assets, and $12.9M other noncurrent assets. Applying standard haircuts: cash/restricted cash ~$560M at 100%; prepaid and other current assets of $18.7M at roughly 50% recovery (~$9M); PP&E at 50% (~$2.9M); ROU assets carry no independent liquidation value; intangibles and R&D pipeline value at zero. Gross liquidated asset value approximates $572M. Total liabilities at face value are $98.1M, including $48.9M current liabilities (accrued liabilities $40.1M, accounts payable $6.0M, employee-related liabilities $9.1M, deferred revenue current $2.8M) and $49.2M noncurrent liabilities (operating lease noncurrent $13.9M, deferred revenue noncurrent $34.3M). Deferred revenue of $37.1M total would not extinguish on wind-up without corresponding service delivery and could remain a claim on the estate. Operating lease obligations total $15.1M on-balance-sheet at ASC 842 carrying value; the undiscounted future minimum commitments are $17.9M through maturity. Finance lease liability is de minimis at $0.8M. Off-balance-sheet purchase commitments of $5.2M (unrecorded unconditional purchase obligations per XBRL tag) add additional wind-up exposure. Net liquidation recovery to equity is positive but thin relative to book equity, approximately $474M-$480M after conservative haircuts — consistent with MFFAIS CLV/LLV of $496M. The period reflects the first quarter post the strategic reprioritization announced March 2026 (30% workforce reduction, 50% expected operating cost reduction). Q1 2026 operating cash burn was $65.9M on revenues of only $0.9M (collaboration), implying a cash runway of roughly 8-9 quarters at current burn before reserves are exhausted, though the company projects reduced burn from the restructuring. Q1 2026 net loss was $60.8M. The accumulated deficit stands at $960.6M. The company has no debt other than lease obligations and the deferred revenue liability stack. The accumulated deficit increased from the prior annual period (10-K as of December 31, 2025, which showed a full-year net loss of $219.0M) — the Q1 2026 loss adds $60.8M to that trajectory. The most significant change quarter-over-quarter is the reduction in cash by $68.6M (from approximately $628M at year-end 2025 implied by the period-decrease tag), partially offset by the expectation of structurally lower operating costs from the workforce reduction. Filing discusses the August 2025 workforce reduction ($5.3M severance) and the March 2026 workforce reduction (~$7.2M expected severance) in MD&A but neither restructuring charge is separately tagged in XBRL as a restructuring liability on the balance sheet as of March 31, 2026.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...